Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane

Key Takeaways Bayer has filed an NDA with the FDA for gadoquatrane, a low-dose gadolinium MRI contrast agent. Gadoquatrane cuts gadolinium dose by about 60% compared to current macrocyclic GBCAs. QUANTI studies showed gadoquatrane improves image quality with no new safety concerns in adults or children.Bayer (BAYRY) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in c ...